Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00193804
Other study ID # TMH/158/2004/Cx_IMRT TRIAL
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 2005
Est. completion date June 30, 2019

Study information

Verified date September 2019
Source Tata Memorial Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A study to evaluate the efficacy of Intensity Modulated Radiation Therapy (IMRT) as compared to Standard Conventional Radiotherapy Alone in the treatment of carcinoma cervix. Concomitant Weekly Cisplatin chemotherapy will be given as a routine, which is a standard of care today for early stage cervical cancers including stage IIB. The benefits of using IMRT in reducing radiation-induced toxicity are well known. Since this treatment modality has not yet been validated and studied in a randomized trial setting, the present study is being undertaken. The study arm of IMRT has the potential to reduce the toxicities by 15-20%, but is associated with labor intense procedure requiring many hospital visits before actual start of treatment.


Description:

Carcinoma Cervix is the commonest malignancy seen in Indian women and constitutes approximately 10% of all cancers at Tata Memorial Hospital (1). It is also the leading cause of cancer mortality in India. Nearly 85% of the patients present with advanced stages (FIGO Stage II/III). The main stay of treatment has traditionally been radical radiation therapy with 80-90% of patients requiring radiation in their lifetime and over decades the survival rates have achieved a plateau of 30 - 55% at 5 years.

Radiation therapy is usually a combination of external beam and intracavitary brachytherapy. External beam radiation includes irradiation of primary tumor and nodal areas of risk. Higher Doses of external beam radiation is limited due to normal critical organs namely, small bowel, rectum and bladder. A major concern with pelvic radiation is the considerable volume of both small bowel and rectum is included in the radiation treatment fields. Unsurprisingly, gastrointestinal radiation reactions include diarrhea while late sequelae include small bowel obstruction, enteritis and diarrhea are common (2-4). The benefits of multiple fields, high energy beams, customized blocking and low fraction sizes are well known (4). Various methods have been used to reduce the small bowel complications. Surgical methods include absorbable meshes (5), tissue expanders (6) and omentoplasty (7). However, these approaches are not feasible in patients undergoing definitive radiation. Apart from small bowel toxicity, late rectal and bladder complications are also of a major concern. The clinical manifestations vary from mild proctitis, stricture, bleeding ulcers and fistula formation to hemorrhagic cystitis requiring cystectomy. Grade III radiation cystitis and proctitis reported are in the range of 3-15% with radiation alone.

Moreover, of late the pattern of practice is increasingly being emphasized on concomitant chemo radiation (8,9). The addition of chemotherapy though has no doubt improved the survivals, but has also led to increase in normal tissue toxicities. In the RTOG 90-01 and 92-10 there is alarming increase in the gastro intestinal (35% grade III and grade IV) and genitourinary (9% grade III and grade IV).

The changes in the treatment policies and the toxicities associated with wide pelvic radiation therapy demand for better normal tissue sparing radiation techniques or radioprotective agents. Three Dimensional Conformal Radiation Therapy (3D-CRT) to some extent has successfully achieved some normal tissue sparing. Intensity-modulated radiotherapy (IMRT) is an important recent advance in radiation therapy and is at the forefront of Translational Research. With 3DCRT the radiation intensity is generally uniform within the radiation portal whereas in IMRT the dose intensity within the portal varies with the use of beamlets, thereby allows a higher degree of conformation to the tumor than previously possible and allows concave isodose profiles to be generated.

Over last 10 years, IMRT has been successfully used in the treatment of prostate, head and neck and brain tumors. IMRT in pelvic radiation has the potential to reduce the dose as well as the volume of rectum, bladder and small bowel irradiated significantly and thereby translating into a decrease in the incidence and severity, of acute and late gastro-intestinal and genito-urinary toxicities. Several dosimetric studies have been reported to confirm the role of IMRT in reducing toxicities with pelvic radiation therapy (10,11). These dosimetric studies have reported that the volume of small bowel irradiated to the prescription dose by a factor of 2 compared with conventional radiation. The average volume of bladder and rectum irradiated is also reduced by 23% (12). In our series of 10 patients treated, IMRT in pelvic radiation therapy apart from reducing the hot spot volumes and better conformity index to the target volume, also significantly reduces the volumes of high dose regions in small bowel region (by 17%), rectum (by 50-60%) and bladder (by 40-50%) [unpublished data]. In another series of early report on outcome of 40 patients treated with IMRT to whole pelvis, Arno el al. have demonstrated that there is a significant reduction in acute radiation related toxicities, but it is too early to comment on late sequelae since the follow-up is short and has concluded that, this novel approach definitely needs to be validated in a trial setting. (13)


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date June 30, 2019
Est. primary completion date June 20, 2017
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Histologically proven squamous carcinoma or adenocarcinoma of cervix

- Performance index WHO grade 0 or 1

- Patients below 65 years of age

- FIGO Stage IIB

- Normal ECG and Cardiovascular system

- Normal hematological parameters

- Normal renal and liver function tests

Exclusion Criteria:

- Co-morbid conditions like medical renal disease

- Medical or Psychological condition that would preclude treatment

- H/o Previous treatment / Pregnancy

- Patient unreliable for treatment completion and follow-up.

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
IMRT
IMRT in cervical cancers

Locations

Country Name City State
India Tata Memorial Hospital Mumbai Maharastra

Sponsors (2)

Lead Sponsor Collaborator
Tata Memorial Hospital Varian Medical Systems

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary To compare the normal tissue toxicities (Acute & Late) of standard radiation therapy with IMRT 2017
Secondary To compare the disease free survivals 2017
Secondary To compare the quality of life in both the groups 2017
Secondary To compare the overall survivals 2017
See also
  Status Clinical Trial Phase
Completed NCT03653819 - High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs N/A
Active, not recruiting NCT00193739 - Neoadjuvant Chemotherapy Followed by Surgery Versus Concurrent Chemoradiation in Carcinoma of the Cervix Phase 3
Not yet recruiting NCT04999696 - Minimally Invasive Therapy Versus Open Radical Hysterectomy for Management of Early Stage Cervical Cancer N/A
Completed NCT02309658 - Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients Phase 2
Completed NCT00193752 - Para-Aortic Lymph Nodal Staging & Evaluation of Treatment Outcome by 18F FDG-PET in Advanced Cancer Cervix N/A
Recruiting NCT00154479 - The Correlation Between the Haplotype of Human Leukocyte Antigen (HLA) and Human Papillomavirus N/A
Recruiting NCT05179824 - Tempus Priority Study: A Pan-tumor Observational Study
Not yet recruiting NCT06147960 - Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer
Completed NCT05149248 - Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study Phase 2/Phase 3
Completed NCT00191100 - Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix Phase 3
Completed NCT00193830 - High Dose Rate (HDR) Versus Low Dose Rate (LDR) Brachytherapy in Carcinoma Cervix Phase 3
Recruiting NCT05742711 - Efficacy of PENS of the Auricle as an Opioid Sparing Postoperative Analgesic Technique in Cancer Endometrium and Cancer Cervix Patients N/A
Completed NCT02865135 - Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer Phase 1/Phase 2
Recruiting NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Not yet recruiting NCT05824494 - Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors Phase 2
Active, not recruiting NCT05709730 - Follow-up of Cell Changes in the Cervix
Completed NCT00193791 - Concomitant Chemoradiation in Advanced Stage Carcinoma Cervix N/A
Withdrawn NCT02312804 - Ph Ib/BGJ398/Cervix and Other Solid Tumors Phase 1
Recruiting NCT03452774 - SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Completed NCT04809727 - Histopathological Findings in Symptomatizing Patients After Supracervical Hysterectomy N/A

External Links